ATRA

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Atara Biotherapeutics, Inc. (ATRA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C
Factor Score 2.3 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.5
EV / EBITDA 76.1
Rev Growth YoY -64.6%
Gross Margin 0.0%
Price Return 3M -26.6%
Price Return 12M -52.2%
Catalyst Signal 0.00
Market Cap $65.2M
TTM Revenue $4.0M
Price / Sales 16.4
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C (2.3) C+ (2.7) D- (0.8) C (2.4) C+ (2.6) C (2.2)
2026-11-10 B (3.3) C+ (2.6) B+ (3.8) B- (2.9) C+ (2.6) B- (3.1)
2026-11-03 B (3.3) C+ (2.6) A- (3.9) B (3.5) C+ (2.7) B (3.2)
2026-10-27 B (3.3) C+ (2.6) A- (3.9) B (3.4) C+ (2.6) B (3.2)
2026-10-20 B (3.3) C+ (2.6) A- (3.9) B (3.4) C+ (2.6) B (3.2)
Page 1 of 6